Telemecine

Chapter 3

Update of Telemedicine for Chronic Heart Failure

Emmanuel Andrès 1,2*, Samy Talha2,3, Mohamed Hajjam4, Amir Hajjam El Hassani5

1Department of Internal Medicine, Diabetes and Metabolic Diseases, Medical Clinic B, Strasbourg University Hospitals (Hôpitaux Universités de Strasbourg [HUS]), Strasbourg, France

2Research Team EA 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Faculty of Medicine of Strasbourg, University of Strasbourg (Universités de Strasbourg [UdS]), Strasbourg, France

3Department of Physiology and Functional Explorations, Strasbourg University Hospitals (Hôpitaux Universités de Strasbourg [HUS]), Strasbourg, France

4PREDIMED Technology, Strasbourg, France

5Research Team EA 4662 “Nanomedicine, Imaging, Therapeutics”, University of Technology Belfort-Montbéliard (University de Technologie de Belfort-Montbéliard [UTBM]), Belfort-Montbéliard, France

*Correspondence to: Emmanuel Andrès, Service de Médecine interne, Diabète et Maladies métaboliques de la clinique médicale B, Hôpitaux Universités de Strasbourg 1, porte de l’Hôpital, 67091 Strasbourg cedex, France
Phone: 33388115066; Email: emmanuel.andres@chru-strasbourg.fr

Abstract

Background: This is a narrative short review of the literature pertaining to telemedicine projects developed in the field of Chronic Heart Failure (CHF), with special attention to non-invasive telemonitoring projects, especially the French projects. Results: Numerous non-invasive telemonitoring projects, based on connected objects or Information and Communication Technology (ICT), have emerged over the last ten years or are under development in the field of CHF. This is the case of the main randomized international telemonitoring studies TELE-HF, TIM-HF and BEAT-HF. This is also the case in France with the telemonitoring projects: SCAD, OSICAT, PIMS, MEDICA and E-care. The E-care project is a French telemonitoring project of new generation. This project support patients returning home after hospital. It fits perfectly within
the framework of telemedicine 2.0 projects, including for the first time Artificial Intelligence (AI). This project has been specifically designed to automatically detect situations at risk for CHF. The potential contribution of these French projects (OSICAT, E-care) is currently under study or documentation, especially in terms of mortality or morbidity, in addition to number of hospitalizations avoided, or economic benefits.

**Keywords:** Telemedicine; Telemonitoring; Artificial Intelligence; Information and Communication Technology; Web, Telemedicine 2.0; Chronic Heart Failure; Diabetes Mellitus; Chronic Disease

1. Introduction

The rising prevalence of chronic diseases; as for example chronic heart failure (CHF) or metabolic disorders, combined with population aging now represents a very real problem for public health (“problème de santé publique”) [1]. A prevalence of over 5.8 million affected people is reported in the US, and over 26 million people worldwide. In France, between 120,000 and 150,000 new cases of CHF are diagnosed every year [2]. The cost of this chronic disease has rocketed, and is estimated, to date, at several billion dollars in developed countries [1].

The management of CHF patients is a challenge for healthcare professionals. In fact, CHF remains a serious disease in terms of their functional or survival prognosis, and of higher morbidity and mortality [1]. Thus, the mortality rate of CHF patients with NYHA stage III–IV is 50% at 5 years (30% in more recent studies) although closer to that of a metastatic breast cancer [2,3].

Moreover, CHF patients frequently present for emergency hospitalization and re-hospitalization [1,2]. In France, CHF is responsible for more than 100,000 hospitalizations per year [2]. It accounts for 5% of all hospitalizations and is the first cause of hospitalization among elderly subjects [2]. Some of these hospitalizations could be avoided if patients have a better followed [1]. This last point has been particularly well documented in CHF [1,4].

The management of CHF needs eat up large amounts of medical resources, just as a shortage in the time careers can provide is beginning to be felt, with medical deserts and a lack of access to healthcare professionals, among other problems.

In this setting, telemedicine may be of really aid. Indeed HF-telemedicine, particularly HF-telemonitoring, may even optimize the management of such chronic disease, particularly by preventing emergency and repeat hospitalizations [2,4].

In this article we review the literature on telemedicine for CHF, with a focus on non-invasive HF-telemonitoring and on French HF-telemedicine projects.
2. Search Strategy

A literature search was performed on the PubMed database of the US National Library of Medicine and on Scholar Google. We searched for articles published between January 2010 and April 2018, using the following key words or associations: “chronic heart failure”, “telemedicine”, “telemonitoring”, “telemedicine in chronic heart failure” and “telemonitoring in chronic heart failure”; restrictions included: English- or French-language publications; published from January 1, 2010 to May 1, 2018; human subjects; clinical trials, review articles or guidelines.

Information and data gleaned from international meetings were also used, as information gleaned from commercial sites on the Web.

All of the English and French abstracts were reviewed by at least two senior researchers from our working group on telemedicine in chronic diseases in the University Hospital of Strasbourg (Strasbourg, France), a referral center. After rigorous selection, only 30 papers were selected and analyzed. Only telemedicine projects meeting rigorous clinical evaluation, e.g. using evidence-based medicine criteria or the criteria usually used for a clinical trial, and completed projects have been included in this work. The latter with additional data gleaned from the Web (references [5-38]) were used to write this chapter in the form of a narrative review. This review is limited by its focus on noninvasive CHF telemonitoring.

3. First Generation HF-telemonitoring Projects

Since the beginning of the 2000’s, numerous telemedicine projects have been conceived and developed in the area of CHF [5-21]. Practically, all of them have investigated “telemonitoring” (or tele management, as it is also known in the literature), as defined under French legislation [22]. It is to note that several papers have been published these late years on this field of medicine as a systematic review [4,16]. Nevertheless to our opinion, these papers do not give a general idea of the studies carried out, since they are mainly based on morbidity and mortality studies (Table 1). To our knowledge, no completed projects have been published on “tele-consultation” and “tele-expertise” in the area of CHF. These terms are defined in Table 2.
Some of the projects have very specifically investigated CHF subjects aged over 75 or over 80 with good results [23,24]. Thus, these later are of special interest in practice (“real life”) because the mean age of the CHF patients is around 80 years in developed countries.

It is worth bearing in mind that those projects, particularly the earlier ones, more closely resembled telephone follow-up with care providers (such as a nurse) traveling to the patient’s home (“structured telephone monitoring” [Table. 2]), rather than telemedicine as we think of it nowadays with nonintrusive, automated, smart telemonitoring using remote sensors via modern communication technology or even artificial intelligence (AI) (“telemedicine 2.0”) (Table. 2) [4, 20]. Hence in our opinion those studies represent the first generation of telemedicine projects [4,14].

Table 1: Potential parameters to be evaluated in a telemedicine project around heart failure.

<table>
<thead>
<tr>
<th>Global mortality</th>
<th>Therapeutic education</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart failure mortality</td>
<td>Hygiene-dietary and therapeutic observance</td>
</tr>
<tr>
<td>Hospitalization for heart failure</td>
<td>Optimization of food and sports hygiene</td>
</tr>
<tr>
<td>Iterative hospitalization for heart failure</td>
<td>Self-patient management</td>
</tr>
<tr>
<td>Number of hospitalization days</td>
<td>Optimization of the fitness trail</td>
</tr>
<tr>
<td>Health cost</td>
<td>Structuring of the fitness trail</td>
</tr>
<tr>
<td>Heart failure management cost</td>
<td>City-hospital relations</td>
</tr>
<tr>
<td>Number of days off work</td>
<td>Information sharing within health professional</td>
</tr>
<tr>
<td>Quality of life</td>
<td>System use by health professionals</td>
</tr>
</tbody>
</table>

Table 2: Glossary of terms and definitions in the field of telemedicine, as proposed by the Italian Association of Hospital Cardiologists, the Italian Society of Cardiology and the Italian Society for Telemedicine and eHealth on telemedicine and as laid out in France in Article 36 of the Social Security Financing (adapted from https://screenshots.firefox.com/6tAymlHs7zDzwkUG/www.ncbi.nlm.nih.gov [consulted in April 2018] and references [1,2]).

**Telemedicine**

Provision of patient care and consultation over a distance using telecommunications technology.

**Telemonitoring (tele-surveillance)**

This telemedicine practice allows a healthcare professional to remotely interpret the data necessary for the medical follow-up of the patient to make decisions about his / her care. Remote data collection from a patient through a connected device or questionnaires to monitor his/her vital parameters and symptoms at home on a daily basis.

**Tele-expertise**

This practice of telemedicine consists, for a medical professional, to seek the opinion of one or more medical professional experts from elements of the medical file of the patient. Remote request by a health professional of a second medical opinion, thanks to the sending of images (scanner, radio, fund of the eye ...) and sometimes to the exchange by videoconference via Internet.

**Tele consultation**

This telemedicine practice allows a medical professional to consult a patient remotely. In the context of a tele consultation, the patient can have at his side a health professional assisting the remote professional as well as a psychologist. Second opinion consultation by specialist.
### 3.1. Clinical impact of first generation non-invasive HF-telemonitoring

As we will see, the results of telemedicine projects in the field of CHF differed from study to study and were fairly inconclusive regarding any potential clinical benefit in terms of, for instance, re-hospitalization or a decrease in morbidity and mortality [5-21]. This particularly applied to the statistical significance of the results. Because of this, the experts had divided opinions about the real utility of telemedicine in the management of CHF patients. Nevertheless, telemedicine is recommended with a low level of evidence for such patient follow-up by the European Society of Cardiology (ESC) [25].

The 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic HF recommend for the first time “remote patient monitoring” of CHF patients with a recommendation of grade II b, level of evidence B [25]. In this setting, telemonitoring is mainly focused on predicting acute decompensation episodes that are usually associated with fluid congestion and require optimization of therapy (titration of angiotensin converting enzyme inhibitors and beta blockers). Clinical practice guidelines on CHF recommend daily weight measurements and include a warning alert when an increased weight of more than 2 kg in a day is observed.

In first telemedicine projects on CHF, it should also be pointed out that the studies were conducted with sometimes inappropriate methodologies, in unsuitable patient groups (such as NYHA stage I) and, above all, in small patient samples (of between 50 and 1000 patients) with very short follow-up periods (of between 3 months and 1 year) [5-21]. Moreover, these studies were built primarily only on weight variations and did not include other studied or warning monitoring parameters (see Table. 2). Thus in our opinion, this made any clinical benefit they demonstrated illusory [4,20].

In 2005, the Trans-European Network - Home-Care Management System study (TEN-HMS) was the first larger study that analyzed the role of telemonitoring in selected patients with HF [26]. In this study, 426 patients were assigned randomly to “telemonitoring”, “nurse telephone support”, or “usual care” in a 2:2:1 ratio. Telemonitoring enabled data transfer (weight, blood pressure, ECG) via a conventional telephone line to a central Web server and

<table>
<thead>
<tr>
<th>Structured telephone monitoring</th>
<th>The basic concept of care extending beyond the health care setting is captured by a simple phone call monitoring strategy wherein patient compliance, symptoms, vital signs, and weight are followed remotely</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telemedicine 2.0</td>
<td>During the last decade, the Internet has become increasingly popular and is now an important part of our daily life. When new “Web 2.0” technologies are used in health or medicine care or in telemedicine, the terms “Health 2.0” or &quot;Medicine 2.0”, and “telemedicine 2.0” or may be used</td>
</tr>
<tr>
<td>Artificial intelligence</td>
<td>This concept is the simulation of human intelligence processes by machines, especially computer systems. These processes include learning (the acquisition of information and rules for using the information), reasoning (using the rules to reach approximate or definite conclusions) and self-correction. Particular applications of AI include expert systems, speech recognition and machine vision.</td>
</tr>
</tbody>
</table>
then via secure intranet connections to a workstation based at each investigator site. Patients were asked to transfer data twice daily. Values greater than or less than predefined limits were signaled automatically to study nurses who could provide advice to the patient directly or, in more severe cases, first inform the primary care physician. In addition to usual care, patients in the group with nurse telephone support were able to contact the HF-specialist nurse by telephone at any time during office hours. Additionally, the nurse contacted the patients by telephone each month in order to assess their symptoms and current medication and to provide advice. In comparison with usual care alone, mortality and re-hospitalization rates were lower in the groups receiving either telemonitoring or nurse telephone support, with no significant differences between both these intervention groups. Of note, the duration of hospital stay and therefore the time until outpatient care was sufficient was 6 days shorter in the group of patients receiving telemonitoring.

Despite these limitations, several reviews and meta-analyses seem to have shown an undeniable utility for telemedicine [4,16]. For instance, Inglis et al. [16] found that telemedicine had an effect on all-cause mortality, which fell significantly by 34% (p<0.0001). In that study, the authors also revealed that re-hospitalization for CHF fell by 20%, that the quality of life of patients and cost of management improved, and that the system was well accepted. In the meta-analysis by Anker et al. [4], 11 studies were analyzed as part of a comparison between the effects of telemonitoring and routine care (non-invasive telemedicine). Their research revealed that telemonitoring led to a reduction of all-cause mortality (10.4% vs. 15.4%; p<0.0001), all-cause hospitalization (47.2% vs. 52.1%; p= 0.02), and hospitalization for CHF (22.4% vs. 28.5%; p= 0.008).

Conversely, three prospective clinical trials, the “gold standard”, have produced results that contradict the previous ones and question the potential utility of telemedicine in CHF [17,18,27] (Table. 3). The Tele-HF study randomized patients hospitalized for CHF to telemonitoring (n = 826) or standard care (n = 827) [17]. Patients were randomized to either voice-based interactive structured telephone support or usual care. Those in the intervention arm were advised to call a toll-free telephone system and answer a series of questions regarding their general health, weight, and HF symptoms on a daily basis. A clinician then analyzed the information. The study found no significant difference between the telemonitoring and standard management groups in terms of all-cause readmission or all-cause mortality in the 180 days after inclusion (odds ratio [OR]: 1.04 [CI95%: 0.91–1.19]) (Figure. 1). The primary outcome, all-cause readmission or death within 180 days after enrollment occurred in 52.3% of the telemonitoring group and 51.5% of the usual care group. However, there was poor adherence despite system generated reminders: 14% of patients in the telemonitoring arm of the study never used the system. By the final week, only 55% of the patients were using the system at least three times a week.
Figure 1: Tele-HF trial (n = 1653 included patients). Primary end point: “Readmission for any reason” and “death from any cause”, and each component separately, according to treatment group (n = 1,653) (adapted from http://www.nejm.org/doi/full/10.1056/NEJMoa1010029 [consulted in May 2018] and reference [17]).

Table 3: Results of the main randomized published international studies of telemonitoring in heart failure.

<table>
<thead>
<tr>
<th>Name of the study</th>
<th>Method</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tele-HF study [17]</strong></td>
<td>Telemonitoring (n = 826) vs. standard care (n = 827)</td>
<td>The study found no significant difference between the telemonitoring and standard management groups in terms of all-cause readmission or all-cause mortality in the 180 days after inclusion (odds ratio [OR]: 1.04 [CI95%: 0.91–1.19]) (p = ns). The primary outcome, all-cause readmission or death within 180 days after enrollment occurred in 52.3% of the telemonitoring group and 51.5% of the usual care group.</td>
</tr>
<tr>
<td><strong>TIM-HF study [18]</strong></td>
<td>Telemonitoring (n = 354) vs. standard care (n = 356)</td>
<td>The all-cause mortality rate was 8.4 per 100 patient-years of follow-up in the telemedicine group and 8.7 per 100 patient-years of follow-up in the standard care group (OR: 0.97 [CI95%: 0.67–1.41]; p = 0.87).</td>
</tr>
<tr>
<td><strong>BEAT-HF Study [27]</strong></td>
<td>“Intervention” group, which included pre discharge HF education, regularly scheduled telephone coaching, and remote monitoring of weight, blood pressure, heart rate, and symptoms (n = 715) vs. usual care group (n = 722)</td>
<td>Readmission for any cause at 180 days occurred in 51% of the group intervention vs. 49% of the control group (p = 0.74). Readmission at 30 days: 23% vs. 22% (p = 0.63), respectively for intervention vs. control and mortality at 30 days: 3.4% vs. 5.4% (p = 0.06), respectively for intervention vs. control. Mortality at 180 days: 14% vs. 16% (p = 0.34), respectively for intervention vs. control.</td>
</tr>
</tbody>
</table>

The TIM-HF study in Germany randomly compared two groups of patients with stable CHF, namely those followed by telemonitoring (n = 354) and those receiving standard care (n = 356) [18]. The TIM-HF trial studied 710 stable CHF patients randomized to either remote monitoring and telephone support or usual care. Patients were given a personal digital assistant (PDA) with a wireless Bluetooth interface. The system collected electrocardiogram data, blood pressure readings, and body weight; this information was then communicated wirelessly to a central location with physician presence 24 h a day, 7 days a week. In that study, the all-cause mortality rate was 8.4 per 100 patient-years of follow-up in the telemedicine group and 8.7 per 100 patient-years of follow-up in the standard care group (OR: 0.97 [CI95%: 0.67–1.41];
p= 0.87) (Figure. 2). The TIM-HF trial was underpowered to detect a significant difference in mortality between the two groups. The composite secondary outcomes of hospitalization for HF and death due to a cardiovascular cause (14.7% vs. 16.5%) highlight the stable nature of the patients recruited in the study given population- and trial-based observations of readmission rates closer to 50%.

Since then, only one large study of this type of remote monitoring has been published, the BEAT-HF trial, which was negative, despite the inclusion of 1,437 patients after cardiac decompensation [27]. In this study, the “intervention” group, which included pre discharge HF education, regularly scheduled telephone coaching, and remote monitoring of weight, blood pressure, heart rate, and symptoms and “usual care” groups did not differ significantly in readmissions for any cause 180 days after discharge, which occurred in 50.8% (363 of 715) and 49.2% (355 of 722) of patients, respectively (adjusted hazard ratio, 1.03; 95% CI, 0.88-1.20; p= 0.74) (Figure. 3). In secondary analyses, there were no significant differences in 30-day readmission or 180-day mortality, but there was a significant difference in 180-day quality of life between the intervention and usual care groups. No adverse events were reported.

Figure 2: TIM-HF trial (n = 710). (A): Primary outcome: “Death from any cause”; and (B): Composite secondary outcome: “Hospitalization for heart failure” or “cardiovascular death” during follow-up. RTM indicates remote telemedical management (adapted from http://circ.ahajournals.org/content/circulationaha/123/17/1873.full.pdf [consulted in May 2018] and reference [17]).
Aside from these medical considerations, it is worth noting that all the studies seem to agree that using telemedicine solutions in the management of CHF was at least economically beneficial (Table. 1) [5-20]. Depending on the study, the savings were calculated to be between $5,000 and more than $50,000/year/patient depending on the stage of CHF and the setting of the study. For instance, in the study by Scalvini et al. [21], the cost of managing CHF patients fell by 24%, and hospital costs fell by €45,186/patient/year. In this setting, the study by Burdese et al. [23] is one of the most convincing for illustrating the utility of tele management in CHF elderly patients. In this study, a significant fall was observed in re-hospitalization (35 without vs. 12 with telemedicine, p= 0.0001), in visits to the emergency department for an acute episode of HF (21 vs. 5/year, p= 0.0001) and in the cost of management (€116,856 vs. €40,065/year). What’s interesting is that only 8.6% of the patients discontinued tele management, showing that it was well accepted.

4. French HF-telemedicine Projects Currently Underway

4.1. General data

Over the last 4 to 5 years, a second generation of projects has emerged in the CHF area, particularly in France [20, 28-33]. These projects are known as “telemedicine 2.0”, because they utilize the new “Information and Communication Technology” (ICT) and the Web. They satisfy the conditions of telemedicine as laid out in France in Article 36 of the Social Security Financing Act (Table. 1) [22].

Most of these projects rely on the usual connected tools for monitoring CHF (“multi-channels” or “multi-sensors”), such as blood pressure meters, weighing scales, and pulse oximeters, which relay the information collected via Bluetooth, 3G or 4G and incorporate tools for interaction between the patient and healthcare professionals like telephone support centers, tablets, and
websites [20]. Some of them also provide tools for motivation and education, and occasionally, questionnaires about symptoms, such as “dyspnea”, “palpitation” and “edema” as experienced by the patient. Most of these studies include “artificial intelligence” (AI) tools or beginnings of articular intelligence.

4.2. Main non-invasive HF-telemonitoring projects in France

The main new telemedicine projects currently being developed in France are:

**SCAD**: “Suivi Cardiologique à Distance” [remote cardiological follow-up], first initiated in 2005, deployed in the low Norman die, France between 2009 April and May 2012, developed by Caen University Hospital (Caen, France) [28];

**PIMPS**: “Plateforme Interactive Médecins patients Santé” [doctor–patient interactive health platform], initiated in 2013, developed by René-Dubos hospital in Pontoise (Pontoise, France) [29];

**OSICAT**: “Optimisation de la Surveillance ambulatoire des Insuffisants CArdiaques par Télécardiologie” [optimization of outpatient monitoring in heart failure patients using telecardiology], initiated in 2012, involving 12 local investigation centers coordinated by Toulouse University Hospital (Toulouse, France) [30];

**MEDICA**: “Monitorage Electronique à Domicile de l’Insuffisance CArdiaque chronique” [electronic home-monitoring of chronic heart failure], initiated in 2014, developed by the REUNICA domicile and GMC-solutions santé groups working in social protection of the elderly [31];

**E-care**: “Detection des situations à risque de décompensation cardiaque chez les patients insuffisants cardiaques de stade III de la NYHA” [detection of risk situations for cardiac decompensation in heart failure patients with NYHA stage-III disease], initiated in 2014, the medical aspects of which were developed by Strasbourg University Hospital (Strasbourg, France) [32,33].

All these projects are run with the aid of the telemedicine 2.0 tools discussed above. The PIMPS project also comprises laboratory monitoring of natriuretic peptide [27]. These projects center on cohorts of CHF patients or prospective studies. They have enrolled relatively large patient samples, and most of them are based on data from evidence-based medicine. The OSICAT study seems the most advanced [30]. It was launched in 2013 and has enrolled 990 patients divided into two groups, remote home-monitoring and controls receiving standard care. The results will include an assessment of medical efficacy and cost-effectiveness, and are expected in 2018.
The E-care telemonitoring project in Strasbourg falls under this category of “telemedicine 2.0” [32,33]. It has been developed to optimize the home-monitoring of CHF patients. It detects situations in which there is a risk of cardiac decompensation and re-hospitalization, and it does this via a telemonitoring 2.0 platform. The E-care platform automatically generates indicators of a worsening of the patient’s “health status”. These “warning alerts” are generated for any decompensation of a chronic disease, particularly CHF, which may lead to hospitalization if not treated. To our knowledge, it is the first project that used “artificial intelligence” (AI) in addition to “information and communication technologies” (ICT). The platform includes connected noninvasive medical sensors, a touch screen tablet that is connected by Wi-Fi and a router or 3G/4G, making it possible to interact with the patient and provide education on treatment, diet and lifestyle (Figure 4). The E-care system includes a server that hosts the patient’s data and a secure Web portal to which the patient and the various hospital- and non-hospital-based healthcare professionals can connect. E-care is based on a smart system comprising an inference engine and a medical ontology for personalized synchronous or asynchronous analysis of data specific to each patient and, if necessary, the sending of an alert generated by AI [34].

**Figure 4**: Version 1 of the generic telemedicine platform developed in the E-care telemonitoring project in heart failure patients. This platform utilized noninvasive medical sensors measuring blood pressure, heart rate, oxygen saturation and weight connected by Bluetooth and relaying real-time physiological data on the patient's health status; touch screen tablets connected by Wi-Fi or 3G/4G; and an Internet server hosting an inference engine that generated the warning alerts. These alerts indicated a deterioration in the patient's chronic diseases, especially chronic heart failure. Health professionals could access them via a secure Internet portal (adapted from http://php52-1.unimedia.fr/centich/uploads/esante.pdf [consulted in May 2018] and reference [32]).

### 4.3. Clinical impact of French non-invasive HF-telemonitoring projects

To date, clinical results are only available for SCAD and E-care projects [28,33,35]. In the SCAD project, 90 patients were randomized from 2009 April to 2011 May (n= 45 for each group) (Thesis from the Faculty of Medicine from Caen, France and reference [28]). The population is elderly, with a mean age of 78 ± 6 years, mostly male (78%) and at high risk of re-hospitalization (mean BNP level of 1,025 ± 950 pg/mL). At 12 months, 1,040 days of hospitalization for acute HF were recorded. Monitoring by educational telemedicine significantly
Telemedicine reduced the number of hospital days for acute HF: 590 days in the “control group” vs. 450 days in the “telemedicine group” (p= 0.044). The criterion “death or hospitalization for acute heart failure” occurred less frequently in the telemedicine group: 57.8% in the “control group” vs. 35.6% in the “telemedicine group” (p<0.05). During CHF readmissions, telemedicine-treated patients had lower intra-hospital mortality: 18.2% vs. 0% (p<0.02).

Between February 2014 and April 2015, 175 patients were given the chance to use the E-care platform [32]. During this period, the E-care platform was used on a daily basis by patients and healthcare professionals according to a defined protocol of use specific to each patient. The mean age of these patients was 72 years and the ratio of men to women was 0.7. The patients suffered from multiple concomitant diseases and had a mean Charlson index of 4.1. The five main diseases were: CHF in more than 60% of the subjects, anemia in more than 40%, atrial fibrillation in 30%, type II diabetes in 30%, and chronic obstructive pulmonary disease in 30%. During the study, 1500 measurements were taken in these 175 patients, which resulted in the E-care system generating 700 alerts in 68 patients [35]. Some 107 subjects (61.1%) had no alerts during follow-up. Analysis of the follow-up of these 107 patients revealed that they had no clinically significant events that might eventually have led to hospitalization. Analysis of the warning alerts showed that the E-care platform automatically and non-intrusively detected any worsening of the patient’s health, particularly CHF. Indeed, it was in this last setting that the system yielded the best sensitivity, specificity, and positive and negative predictive values, respectively 100%, 72%, 90% and 100%. The E-care platform also showed its ability to detect a deterioration in health status via the multiple diseases of the patients studied, with sensitivity, specificity, and positive and negative predictive values of, respectively 100%, 30%, 89% and 100%.

5. Perspectives on New Telemedicine Projects in France

5.1. In the field of chronic heart disease

As discussed above, the E-care platform appears to be capable of preventing hospitalization by detecting any deterioration in the patient’s health status early and by making it possible for the care providers in charge of the patient to be warned and, above all, to intervene [32,33]. The E-care platform as others’ currently underway is also capable of structuring the patients’ cares pathways, a major theme in medicine for our governments and authorities (Table. 1). It is also capable of providing a means for the various healthcare professionals to exchange with each other; and of facilitating access to medical resources.

With this in mind, an enhanced version of the E-care platform will be experimented in the homes of heart failure patients as part of a project called PRADO INCADO (Figure.5) [34]. The project is being run by a group bringing together Strasbourg University Hospital, the Alsatian regional health agency, the Bas-Rhin branch of France’s national health insurance, and
the company PREDIMED Technology. This project will allow us to conduct an in-depth study so as to improve diagnosis by aiding machine learning and, therefore, detect abnormalities early.

This is in keeping with the research of Mortazavi et al. on the utility of AI in managing CHF patients, particularly the possibility afforded by artificial intelligence of predicting re-hospitalization for CHF [36].

5.2. In the field of diabetes mellitus

Diabetes and metabolic disorders are other fields of priority investigation of telemedicine in France, outside CHF. Innovative projects are being developed or deployed, such as the PLASIDIA platform, run by the European Center for the Study of Diabetes in Strasbourg (France) [37]. It is in this setting, we developed an up graduate version of the E-care platform to follow patients suffered from diabetes mellitus under the DIABETe project. The new version of the E-care platform should be deployed in “complex diabetic” patients; e.g. diabetic patients with high cardiovascular risk or diabetic patients treated with multiple injections [38]. Most of these patients potentially may present an episode of HF and perhaps CHF during long-term follow-up.

The objective of the DIABETe project is to detect early the risk of hospitalization of diabetic patients with a “very high cardiovascular risk”: personal history of myocardial infarction (MI) or stroke, and/or limbs amputation and/or cardiomyopathy with “intensive” insulin therapy (minimum of 3 injections per day or pump), through a personalized follow-
up and accompany the patient in the knowledge of his illness and his management [38]. This population is interesting because it allows targeting poly-pathology and poly-medication. It requires global support. It represents 50% of diabetics hospitalized in departments of Diabetology and Internal Medicine. Apart from cardiovascular complications (MI, arteritis obliterans of the lower limbs, etc.), they are also hospitalized for hypoglycemia, imbalance of diabetes, iatrogenic, infections, etc.

The DIABETe project is based on an intelligent platform that will assist the medical profession by automating the processing of information from non-intrusive medical sensors (blood glucose meter, blood pressure monitor, actimeter, connected scale, etc.) as well as subjective information from the patient himself (questionnaires) and its behavior (compliance) to detect and report these situations at risk of hospitalization early [38]. Therapeutic education tools adapted to the patient and the situation will be made available to the individual. Communication to the subject will be provided by a touch pad. Alerts testifying to a deterioration of the patient’s condition will be generated by AI and reported to health professionals in charge of the patient, to anticipate the decompensation and to afford the means of care outside the emergency setting. These solutions, derived from new technologies, will be innovative and original to offer the best acceptability by patients. It will allow the sharing of medical data between health professionals as part of a city-hospital network. Ultimately, it should also lead to an improvement in the quality of life of the patient.

DIABETe does not compete with Diabeo or other expert systems whose purpose is to optimize the glycemic balance, which in itself is one of the essential objectives of diabetes mellitus [39]. The DIABETe project aims at “global” management of the diabetic patient through the detection of situations at risk of hospitalization: infection, cardiac decompensation, diabetic foot, etc. but also of course hypoglycemia and hyperglycemia leading to hospitalizations. It should also be noted that the remote monitoring platform used in DIABETe is likely to integrate or interface with expert systems such as Diabeo. As a reminder, the Diabeo application, carried by SANOFI, was tested as part of the Télésage clinical trial for 700 patients with DT1 and DT2, under a basal bolus regimen (multi-injection or pump) [39]. The main criterion of the Télésage study is the variation of HbA1c (glycemic control) at one year. A previous study, Télédiaib1, conducted between 2007

6. Conclusions

Although many non-invasive telemonitoring projects have been conducted in the CHF area, relatively few have been conducted in the setting of telemedicine 2.0 with aid of ICT and Internet. The E-care telemonitoring project is one that wholly falls under this category. Their potential utility in terms of morbidity, mortality and avoidance of hospital admissions is being studied or documented. Their impact in terms of health savings is also being assessed.
The telemedicine 2.0 projects are perfectly compatible with the care pathways being developed in chronic diseases by the French health authorities (including the French ministry of health and the regional branch of the national health insurance). What’s more, all these findings should be analyzed with regard to the benefit of these telemedicine solutions (Table 1).

This experience may lead us to witness the birth of the medicine of tomorrow. In the field of chronic diseases, given the epidemiology and expected shortage of time careers can provide, what we need is better follow-up and better education, improved prevention and anticipation, but, above all, better selection of the patients whose use of the healthcare system will be indispensable.

7. Declarations

Competing Interests: M. Hajjam is the scientific Director of PREDIMED Technology.

Funding: Grant from the Agence Régionale de Santé du Grand-Est. Grant from the Fondation de l’Avenir. Grant from the Agence Nationale pour la Recherche (ANR) Technologie

Ethical approval: Not applicable.

Guarantor: EA.

Contributor ship: EA and ST designed the study and conducted the searches. EA, ST and AH composed the results and parts of the discussion. ST, MH and AH provided critical analysis and revising of all portions of the manuscript and authorized the final version for publication. EA is responsible for all revisions and maintains contact with the rest of the review team with status reports.

8. References


31. Protect your health, your retirement, your wealth and your loved ones with ag2r la mondiale. 2018.


37. Plasidia, the personalized telemedicine platform for diabetics. 2017.
